Delcath Systems combines a profitable, 90%-gross-margin HEPZATO franchise with a debt-free balance sheet and potentially transformational colorectal and breast cancer pipeline optionality.
Overview
Delcath Systems is an interventional oncology company commercializing liver-directed PHP through HEPZATO in the United States and CHEMOSAT in Europe. The platform isolates hepatic circulation, delivers exceptionally high-dose melphalan, and filters the drug before systemic return, providing localized tumor treatment with limited systemic exposure. **Commercial execution has reached an important inflection point:** Q2 2026 revenue rose 20.6% year over year to $29.13 million, beat consensus by approximately 11%, and included $2.67 million of GAAP net income and $0.07 diluted EPS versus an expected loss of $0.09. Gross margin reached 90.0%, while operating cash flow was $5.73 million. HEPZATO represented $27.16 million, or 93.1%, of revenue, and the active-center network reached 31, with approximately 37 targeted by year-end. Management raised 2026 revenue guidance to $104 million-$108 million and reaffirmed positive adjusted EBITDA. The balance sheet contained $95.90 million of cash and investments and zero debt. Valuation is driven by a 20.0% modeled five-year sales CAGR, high-margin operating leverage, and pipeline expansion. The main catalysts are center growth, stable ASP near $175,000, DEL-LIVER data expected in late 2027, and DELUMA progress; key risks are 340B pricing, clinical failure, dilution, and procedure-adoption friction.